Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967355 | 0.81 | L3MBTL1 (0.39) | HTTL3MBTL1KDM4EADORA1ATM | |
| SCHEMBL3969946 | 0.80 | GAA (0.50) | HTTL3MBTL1KDM4EADORA1ATM | |
| SCHEMBL3966666 | 0.78 | L3MBTL1 (0.36) | HTTL3MBTL1KDM4EADORA1ATM | |
| SCHEMBL3964910 | 0.78 | ADORA1 (0.43) | HTTL3MBTL1KDM4EADORA1NPC1 | |
| SCHEMBL3926799 | 0.77 | ATM (0.37) | HTTL3MBTL1KDM4EADORA1ATM | |
| SCHEMBL3963052 | 0.76 | TMIGD3 (0.38) | HTTL3MBTL1KDM4EADORA1NPC1 | |
| SCHEMBL4694453 | 0.75 | S1PR1 (0.38) | HTTL3MBTL1ATMNPC1RAB9A | |
| SCHEMBL3966602 | 0.75 | ATM (0.36) | HTTL3MBTL1KDM4EADORA1ATM | |
| SCHEMBL19913061 | 0.73 | CNR2 (0.46) | KDM4ENPC1RAB9AGAAMAPT | |
| SCHEMBL10172955 | 0.70 | NPC1 (0.53) | HTTL3MBTL1KDM4EADORA1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233839-B1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-25 | — | — | EP | disclosed |
| US-7557103-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| EP-1879896-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006107784-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153828-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | HTT 1254/4885L3MBTL1 4787/4885KDM4E 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.